ibogaine News & Analysis
2 articles
Market Mood
Trump's Order Accelerates FDA Review of Ibogaine and Psychedelics
On April 18, 2026, President Trump signed an executive order to expedite U.S. federal reviews of psychedelics, including ibogaine, aimed at improving medical research and clinical trials. The FDA plans to issue national priority vouchers next week for three psychedelics, allowing for accelerated approval if aligned with national priorities. Ibogaine is currently classified as a high-risk drug and is banned federally, but advocates believe it could benefit conditions like PTSD and opioid addiction. This directive marks the FDA's first fast-tracking initiative for psychedelics, reflecting a shift in policy toward potential treatment options.
Read More
Trump Psychedelic Drug Executive Order Expected Soon
Former President Donald Trump is expected to sign an executive order aimed at easing restrictions on the use of psychedelic drugs, including psilocybin and ibogaine. This move is anticipated to facilitate research into these substances, particularly their potential for treating PTSD. While specific timing for the executive order has not been announced, it signifies a shift in regulatory attitudes towards psychedelics that could impact healthcare markets. Such changes may lead to increased investment and research opportunities within the pharmaceutical sector.
Read More